title: Second primary cancers following non-Hodgkin's lymphoma in Japan: increased risk of hepatocellular carcinoma.
abstract: We evaluated the risk of development of second primary cancers, with particular reference to subsequent hepatocellular carcinoma (HCC), in 592 patients diagnosed as non-Hodgkin's lymphoma (NHL), at Osaka Medical Center for Cancer and Cardiovascular Diseases. During 1978-1994, 2,163 person-years of observation were accrued, and 27 of the patients developed a second primary cancer, yielding an observed-to-expected ratio (O/E) of 1.53 [95% confidence interval (CI) = 1.01-2.23]. Significant excess risk was noted for primary liver cancer (PLC; O/E = 4.36, 95% CI = 1.99-8.28; O = 9) and non-lymphocytic leukemia (O/E = 26.17, 95% CI = 5.26-76.46; O = 3). The excess risk of PLC was relatively constant within the first 10 years after the NHL diagnosis. Patients who received chemotherapy as the NHL treatment had a significantly increased risk of PLC (O/E = 5.91, 95% CI = 2.70-11.23; O = 9). Their clinical reports indicated that all nine patients with PLC were diagnosed as HCC, and eight of them had clinical and/or histologic evidence of cirrhosis at the time of HCC diagnosis. None of the nine patients had a history of blood transfusion between the first NHL treatment and the diagnosis of HCC. These findings suggested that Japanese NHL patients might have an increased risk of developing HCC, and they indicated the importance of medical surveillance for liver malignancies, as well as subsequent leukemias. Possible explanations for the excess risk of subsequent HCC are discussed.
authors.affiliation: Department of Cancer Control, Osaka Medical Center for Cancer and Cardiovascular Diseases, Center for Adult Diseases.
authors.forename: H
authors.initials: H
authors.lastname: Tanaka
authors.forename: H
authors.initials: H
authors.lastname: Tsukuma
authors.forename: H
authors.initials: H
authors.lastname: Teshima
authors.forename: W
authors.initials: W
authors.lastname: Ajiki
authors.forename: Y
authors.initials: Y
authors.lastname: Koyama
authors.forename: N
authors.initials: N
authors.lastname: Kinoshita
authors.forename: T
authors.initials: T
authors.lastname: Masaoka
authors.forename: A
authors.initials: A
authors.lastname: Oshima
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000453:epidemiology*; D016001:Confidence Intervals; D005500:Follow-Up Studies; D006801:Humans; D007564:Japan / Q000453:epidemiology; D007680:Kidney Neoplasms / Q000453:epidemiology; D007938:Leukemia / Q000453:epidemiology; D008113:Liver Neoplasms / Q000453:epidemiology*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000453:epidemiology*; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors